drugset / Trial / NCT07303660
A Phase 1b Study of Lonitoclax + Azacitidine in Acute Myeloid Leukemia Patients
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a clinical study aiming to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of ZE50-0134 in relapsed and refractory Acute Myeloid Leukemia patients.
Timeline
- Start
- 2026-01-10
- Primary completion
- 2026-09
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | — |
| Subject | Lonitoclax | Unknown | — | Oral |